O
ACET icon

OppenheimerFunds’s Adicet Bio ACET Stock Holding History

OppenheimerFunds’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$29.4M Buy
+38,541
New +$35M 0.04% 442

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Segantii Capital Management Hong Kong $1.54B AUM 16.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

OppenheimerFunds's ACET Position: Q1 2019 in Review

OppenheimerFunds opened a new position in Adicet Bio (ACET) in Q1 2019: 38,541 shares worth $29.4M. The stake represents 0.04% of the portfolio and ranks #442 among its holdings.

49 funds tracked by Wall St. Rank hold ACET as of Q1 2019.

  • OppenheimerFunds held 38,541 shares of Adicet Bio worth $29.4M as of Q1 2019.
  • Adicet Bio was a new OppenheimerFunds position in Q1 2019.
  • Adicet Bio made up 0.04% of OppenheimerFunds's portfolio in Q1 2019, its #442 holding.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.